Paclitaxel (Taxol®) for the treatment of lymphoma

A. Younes, J. P. Ayoub, A. Sarris, L. North, O. Pate, P. McLaughlin, M. A. Rodriguez, J. Romaguera, F. Hagemeister, C. Bachier, A. Preti, F. Cabanillas

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Paclitaxel (Taxol®) was recently tested in patients with relapsed and refractory lymphoma in two phase II clinical trials using two different infusion schedules. The first, reported from the NCI (USA), used a 96-hour intravenous continuous infusion schedule, and the second, from our group, used a 3-hour infusion. In the NCI trial, 29 evaluable patients were treated with 140 mg/m2 every three weeks, which achieved a 17% response rate (all PRs); while we treated 96 evaluable patients with 200 mg/m2 every three weeks, which achieved a 25% response rate (10 CRs and 14 PRs, 95% CI: 17%- 35%). In our trial, patients with relapsed (not primary refractory) intermediate-grade lymphoma had a response rate of 50%, and those with relapsed low-grade lymphoma had a response rate of 31%. In a follow-up trial, 12 patients who failed to respond to 3-hour infusion of paclitaxel were crossed over to receive paclitaxel by 96-hour infusion. None of the 12 evaluable patients achieved a major clinical response. Similarly, of 25 patients treated with cyclosporine A and paclitaxel after failing therapy with single-agent paclitaxel, only one patient (4%) responded. We conclude that paclitaxel has a promising single-agent activity most prominently in patients with relapsed intermediate-grade lymphoma. Paclitaxel-based combination programs are currently being evaluated in our institution.

Original languageEnglish (US)
Pages (from-to)S129-S131
JournalAnnals of Oncology
Issue numberSUPPL. 1
StatePublished - 1997


  • lymphoma
  • paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Paclitaxel (Taxol®) for the treatment of lymphoma'. Together they form a unique fingerprint.

Cite this